The device, which was recently approved by the FDA, uses pulsed electric fields to efficiently and safely treat A-fib, according to a Nov. 19 press release.
The procedure was successfully performed on Sept. 9 at Northside Hospital Atlanta by cardiac electrophysiologist Alok Gambhir, MD.
Unlike traditional ablation technologies that rely on heat and risk damaging surrounding tissues, Medtronic’s non-thermal mechanism reduces the potential for collateral damage.
Atrial fibrillation currently impacts 59 million people worldwide, and can worsen overtime without early intervention.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.